Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression
- DOI
- 10.3389/fonc.2022.987643
- Published
- 2022-09-21
- Container
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fonc.2022.987643,
title = {Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression},
author = {Alessandro Malara and Cristian Gruppi and Margherita Massa and Maria Enrica Tira and Vittorio Rosti and Alessandra Balduini and Giovanni Barosi},
year = {2022},
journal = {Frontiers in Oncology},
doi = {10.3389/fonc.2022.987643},
url = {https://doi.org/10.3389/fonc.2022.987643}
}RIS
TY - JOUR TI - Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression AU - Alessandro Malara AU - Cristian Gruppi AU - Margherita Massa AU - Maria Enrica Tira AU - Vittorio Rosti AU - Alessandra Balduini AU - Giovanni Barosi PY - 2022 JO - Frontiers in Oncology DO - 10.3389/fonc.2022.987643 UR - https://doi.org/10.3389/fonc.2022.987643 ER -
APA
Malara, A., Gruppi, C., Massa, M., Tira, M. E., Rosti, V., Balduini, A., & Barosi, G. (2022). Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression. Frontiers in Oncology. https://doi.org/10.3389/fonc.2022.987643
Source records
- crossref · retrieved 2026-11-11T02:00:40.644Z